494
Participants
Start Date
November 20, 2023
Primary Completion Date
September 12, 2029
Study Completion Date
September 12, 2030
PF-08046050
Given into the vein (IV; intravenous)
bevacizumab
Given into the vein (IV; intravenous)
RECRUITING
ApoEx NKS, Stockholm
RECRUITING
Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
RECRUITING
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid
RECRUITING
Florida Cancer Specialists, Orlando
RECRUITING
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
RECRUITING
Sarah Cannon Research Institute - Pharmacy, Nashville
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
START Midwest, Grand Rapids
RECRUITING
Mayo Clinic Cancer Center, Rochester
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
South Texas Accelerated Research Therapeutics, LLC, San Antonio
RECRUITING
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
RECRUITING
University of Colorado Hospital/University of Colorado, Aurora
RECRUITING
South Texas Accelerated Research Therapeutics Mountain Region, West Valley City
RECRUITING
Mayo Clinic Hospital, Phoenix
RECRUITING
Mayo Clinic, Scottsdale
RECRUITING
City of Hope, Duarte
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
The Ottawa Hospital, Ottawa
RECRUITING
University Health Network, Princess Margaret Hospital, Toronto
RECRUITING
McGill University Health Centre, Montreal
RECRUITING
Netherlands Cancer Institute, Amsterdam
RECRUITING
Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), L'Hospitalet de Llobregat
RECRUITING
Karolinska University Hospital, Solna
RECRUITING
The University of Edinburgh, Edinburgh
RECRUITING
Sarah Cannon Research Institute UK, London
Collaborators (1)
Sanofi
INDUSTRY
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY